Member Since 2018
Richard A. Gonzalez
Chairman & CEORichard A. Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company that employs approximately 50,000 people worldwide and markets medicines in more than 175 countries.
Prior to AbbVie’s separation from Abbott in January 2013, Mr. Gonzalez was a 30-year Abbott veteran. He served as President and Chief Operating Officer of Abbott before briefly retiring in 2007. He also held various senior leadership positions in Abbott’s medical products businesses, including President and Chief Operating Officer of the Medical Products Group; Senior Vice President and President of the former Hospital Products Division; Vice President and President of the Health Systems Division; and Divisional Vice President and General Manager for Diagnostics Operations in the United States and Canada.
Mr. Gonzalez has been a long-standing leader in the greater Chicago community where he is a member of the Commercial Club of Chicago and represents AbbVie on their Civic Committee. He is also a member of the Business Roundtable, which is the only national organization representing exclusively CEOs of America’s leading companies.Abbvie
Abbvie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.
Member since 2020
Randy Trice
Chief Executive OfficerRandy Trice is the CEO of Alphanumeric Systems, Inc., where he shapes the company’s corporate direction, performance, and vision. Under his strategic leadership, Alphanumeric has experienced significant growth, operational excellence, and increased market influence. Randy cultivates a culture of performance, ownership, and success, inspiring his team to achieve outstanding results. His dedication to expanding market share, revenue, and EBITDA, coupled with his strategic insight and decisive action, has steered Alphanumeric through both growth and challenges.
During his tenure, Randy’s leadership at Alphanumeric has significantly boosted both market share and profitability through strategic partnerships and alliances. Under his guidance, the company has also expanded into new global markets, paving the way for future opportunities. In 2022, Alphanumeric’s rapid growth was acknowledged by the Triangle Business Journal, earning the top spot in the Fast 50 Award for the highest percentage growth over a two-year period.
Beyond his role at Alphanumeric, Randy is an active member of the CEO Roundtable on Cancer, contributing to the company’s Gold Standard Accreditation. He is also committed to youth empowerment, serving as a Board Member and Business and Finance Committee Member of the Wake County Boys & Girls Club.CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Employer Since 2022"It’s great to be able to say that we are among the leaders in our industry when it comes down not only to execution but also to policy and procedure- two things that set us apart. The accreditation is an honorable nod towards the caliber of people we work with in the pharma and life sciences spaces in North Carolina and globally."
Randy TriceAlphanumeric
Alphanumeric Systems, Inc. stands as a distinguished leader in the healthcare and life sciences sectors, dedicated to propelling organizations toward a future marked by greater efficiency and personalized patient care. Founded in 1979, Alphanumeric started as an IT services company and has since evolved into a vital partner within the life sciences and healthcare industry. Their extensive expertise includes customer communication hubs, digital transformation, medical communications, and technical services aimed at enhancing patient engagement, satisfaction, and empowerment. In 2022, Alphanumeric expanded its global presence by opening its 11th location, reaffirming its commitment to patient care. This dedication has garnered widespread recognition, including their induction into the CEO Roundtable on Cancer’s Gold Standard and numerous other prestigious awards, showcasing their relentless pursuit of excellence and innovation in healthcare.
Founding Member
Robert A. Bradway
Chairman, CEO Roundtable on Cancer
Chairman of the Board, President and Chief Executive Officer, Amgen, Inc.Robert A. Bradway is Amgen’s chairman and chief executive officer. Bradway became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010.
Prior to joining Amgen, he was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990.
He is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university. He is the chairman of the CEO Roundtable on Cancer, a non-profit organization comprised of executives founded to bring solutions to cancer treatment and prevention. He is a member of the American Heart Association CEO Roundtable on Cancer, which is helping the Association meet its goal of improving the cardiovascular health of all Americans. He is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors.
Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Employer Since 2014 | Gold Standard – China Employer Since 2017"We are honored to join other leading organizations in the commitment to a healthy workforce as a CEO Cancer Gold Standard accredited corporation. Our mission at Amgen is to serve patients, especially those suffering from serious illness, which makes us acutely aware of the toll cancer can have on patients and their loved ones. In addition to numerous health and wellness programs for our staff members, Amgen supports educational programs and resources ranging from prevention to survivorship for those outside of our company who are affected by cancer."
Robert A. BradwayLife Sciences Consortium
LSC Task Force Participation
Life Sciences Consortium Co-Chair: David Reese MD, Executive Vice President of Research & Development.
Task Force Members: Gregory Friberg MD, Global Product General Manager; Raymond C. Jordan, Senior Vice President & Corporate AffairProject Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumData Provider
Since 2015
Communications Support for Project Data Sphere, LLC, 2016-2017AMGEN
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Member Since 2018
Peter Sandor
Vice President Oncology, Marketing StrategyPeter Sandor Vice President, Head of Oncology Therapeutic Area Marketing Strategy. In this role, Peter provides commercial leadership for project’s within the oncology therapeutic area and plays an integral role in the expansion of Astellas’s presence in oncology.
Peter has 20 years of progressive marketing experience. He was recently the Vice President, Global Marketing Oncology at Amgen responsible for the successful realization of the commercial potential for Amgen’s oncology assets. Prior to Amgen, he has held different positions at Bayer Healthcare, including Head of Strategy and Portfolio Management Specialty Medicine, Commercial Development and Life Cycle Management Global Oncology. He also worked for Berlex Laboratories as the lead of the global launch team for a key oncology compound, and held multiple marketing roles with Schering AG in Germany and Hungary.
Peter started his career in bench research as a scientific advisor of the Hungarian Academy. He received his MDS Marketing and MBA from Middlesex University, London and Faculty of Business and Economy, University of Pécs, Hungary, and his MD from University of Pécs, Hungary.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2012Gold Standard Task force Participation
Task Force Member: Tom Mais, Associate Benefits DirectorLife Sciences Consortium
LSC Task Force Participation
Task Force Member: Peter Sandor MD, Vice President, OncologyAstellas Pharmaceutical, Inc.
Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms – Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate. For more information about Astellas Pharma US, Inc., please visit our Web site at www.astellas.us.
Member Since 2004
David Fredrickson
Executive Vice-President, Global Head Oncology Business UnitDave Fredrickson was appointed EVP, Global Head Oncology Business Unit in October 2017 and is responsible for driving growth and maximizing commercial performance of the global oncology and hematology portfolio within AstraZeneca. In addition, he plays a critical leadership role in setting the Oncology portfolio and product strategy for the organization.
Prior to this role, Dave served as President of AstraZeneca K.K. in Japan, and Vice President, Specialty Care for AstraZeneca in the United States, spanning oncology, infection disease, and neuroscience medicines. Dave joined AstraZeneca from Roche/Genentech in 2014, where he was Business Unit Manager, Oncology in Spain and held growing commercial responsibilities in strategy, marketing and sales in the US. He also served for nine years at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy. He has served as Vice Chairman of European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan and was a member of the Board of the Japan Pharmaceutical Manufacturers Association (JPMA). He is a graduate of Georgetown University (DC) in Government.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2006Life Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Andrew Coop. Vice President, US Medical Affairs; David Fredrickson, Executive Vice President & Global Head of Oncology; Michelle Werner MBA, Country President for Nordics & Baltic Markets in Europe; Nevine Zariffa, Vice PresidentProject Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumData Provider
Pioneering Data ProviderAstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that spans the discovery, development, manufacturing, distribution and worldwide commercialization of primary care and specialty care medicines.
We believe the best way we can help patients is to focus on breakthrough science in order to uncover disease mechanisms and develop novel, targeted therapies that interact with them. This is at the heart of our purpose as a company: to push the boundaries of science to deliver life-changing medicines.
We invest in distinctive science in three main therapy areas where we believe we can make the most meaningful difference to patients: oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity. Our science exploits our rare combination of capabilities in small molecules and biologics, immunotherapies, protein engineering technologies and devices. These are reinforced by a strong focus on translational science and personalized healthcare capabilities. We build on our own capabilities by collaborating with world-renowned scientists and academic institutions and partnering with like-minded science-led companies.
Through leading in science, we are confident that we can transform the lives of people around the world and deliver value to our shareholders.
For more information, visit www.astrazeneca.com.
Specialties
Pharmaceutical, Biopharmaceutical, Innovation, Research and development, Global business
Website
http://www.astrazeneca.com
Member Since 2020
Dr. Robert J. Brown
CEO and FounderDr. Robert Brown is Chief Executive Officer of B&C International (BCI). Throughout his career, Dr. Brown has spent significant time solving problems and cultivating key high level relationships in the United States and on the continents of Africa, Asia and Europe. As BCI’s visionary, he continues to strategically support company platform development, global growth and client engagements.
He also serves as an Ambassador for the CEO Roundtable on Cancer’s Going for Gold initiative, which is focused on improving health equity, education, navigation, and access to care in partnership with academic institutions.
Dr. Brown speaks frequently on race relations, emerging markets and international strategy and was recognized by the Washington Post as a World Class Power Broker. Recently retiring from the boards of the NCAA, Duke Energy, Wachovia Corporation, Wake Forest University Baptist Medical Center and Sonoco Products Company, Dr. Brown is a strong supporter of youth, education and non-violent programs. Dr. Brown currently serves on the boards of High Point University, Boston University, Virginia Union University, National Urban League, Horatio Alger Association and the Richard Nixon Foundation.
Numerous colleges, universities and national organizations have honored Brown. He holds ten honorary doctorate degrees and six national achievement awards. He has also been honored as a recipient of the Horatio Alger Association of Distinguished Americans Award, the Small Business Administration’s Lifetime Achievement Award, the United Way of Greater High Point’s 2002 Alexis de Tocqueville Society Award, The High Point Enterprise 2005 Citizen of the Year Award, the U.S. Department of Commerce’s Minority Business Development Agency’s 2006 Abe Venable Legacy Award for Lifetime Achievement, the U.S. Department of Commerce Minority Business Development Agency’s 2007 National Director’s Legacy Award for Lifetime Achievement and the National Urban League’s 2009 Collins Award.B&C International
B&C International is a Global Strategy and Business Management Consulting firm headquartered in High Point, North Carolina. During the last 55 years of our existence, the methodologies and tools we use to help our clients efficiently solve problems has evolved, but our core principles remain the same. We are trusted advisors. As the “1st Call” for client concerns, our systematic approach to aligning culture, communication and execution, allows you to gain confidence, clarity and consistency for strategic decision-making.
We understand the value of Human Capital. B&C’s unique people-centered techniques allow you to grow and innovate through overcoming market maturity issues, capitalizing on expansion opportunities, building business models that work for your culture, eliminating departmental silos, maximizing current staffing level productivity, improving the internal interface between baby boomers and millennials, redesigning business models without abandoning who you are, developing a culture of change and accountability, and deepening customer connectivity. We use our influential relationships, resources and staff to assist you in achieving your goals.
Member Since 2004
Robert LaCaze
Executive Vice President, Oncology Strategic Business UnitRobert joined Bayer as SVP, Head of Oncology TA in October 2015. He has more than 27 years of bio-pharmaceutical experiences most of which has been spent in specialty areas, mainly Oncology. Before joining Bayer, Robert was the SVP, Global Oncology with Bristol-Myers Squibb and co-led the Oncology Disease Strategy team with direct responsible to set the vision, strategy, and execution for the Immuno-Oncology (I-O) Franchise at BMS.
Robert currently serves on the Louisiana Tech College of Business Administration Advisory Board and is a member of AACR and BioNJ. He, his wife and two sons reside in Robbinsville, New Jersey.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2014Bayer HealthCare is committed to delivering Science For A Better Life by advancing a portfolio of innovative treatments that offer meaningful progress to doctors and patients battling the toughest cancers. The Gold Standard recognition by the CEO Roundtable on Cancer underscores our commitment to fighting cancer, through our Oncology portfolio and ongoing efforts to provide employees with the education and healthcare they need to be as healthy as possible.
Robert LaCazeLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Bhavesh Ashar; Senior Vice President and Head, Oncology; Chandra Ramanathan PHD MBA, Vice President and Head, East Coast Innovation Center; Robert LaCaze, Executive VP, Oncology Strategic Business Uni; Svetlana Kobina MD PhDProject Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumData Provider
Since 2014Bayer HealthCare
Bayer HealthCare Pharmaceuticals Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products for diagnosing, preventing, and treating diseases for human health. The company focuses on women’s healthcare, diagnostic imaging, general medicine, hematology/neurology, and oncology products. It provides NEXAVAR, an anticancer medicine used to treat kidney cancer; Stivarga regorafenib tablets for the treatment of patients with metastatic colorectal cancer; Aflibercept (Eylea), an anti-angiogenic therapy for wAMD patients; Xofigo (radium Ra 223 dichloride), an alpha particle-emitting radioactive therapeutic agent for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and visceral metastatic diseases; Gadavist, a gadolinium-based contrast agent for pediatric patients; and Dienogest to treat endometriosis in women. Bayer HealthCare Pharmaceuticals Inc. has a strategic alliance with Broad Institute. The company was founded in 1979 and is headquartered in Wayne, New Jersey. Bayer HealthCare Pharmaceuticals Inc. operates as a subsidiary of Bayer AG.
Member Since 2022
David M. Epstein, PhD
Co-Founder, President and Chief Executive OfficerDavid M. Epstein, Ph.D., is a biopharmaceutical leader and executive who has successfully led R&D teams in academic, start-up, mid-size, and global large-pharmaceutical settings for over 20 years. Epstein is a Founder of Black Diamond Therapeutics and took the Company public on the NASDQ Global Market in January 2020, having cumulatively raised over $400 million in private and public financing.
Prior to his appointment as Black Diamond’s President and CEO, Epstein was Vice Dean, Innovation & Entrepreneurship, at Duke-NUS Medical School, Singapore, establishing the Centre for Technology & Development and building a pipeline of venture-backed companies. Epstein was Associate Professor in the Cancer & Stem Cell Biology Program at Duke-NUS where he established a research program focused on the role of defective mRNA splicing in cancer. This work resulted in the simultaneous discovery of splicing-derived shared tumor antigens and their cognate TCR pairs, which has led to the founding of PairX Bio, a venture-backed Precision Immuno-Oncology company. Previously, he was Chief Scientific Officer at OSI Pharmaceuticals, acquired by Astellas Pharma for over $4 billion in 2010, and was a founder and senior executive at Archemix Corp. Epstein’s R&D teams have progressed more than a dozen novel agents through clinical development in oncology, cardiovascular disease, and retinal degeneration.
Epstein earned a Ph.D. in Biochemistry at Brandeis University and led a joint post-doctoral fellowship in protein structure-function and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla, California. He received a B.Sc. in Chemistry from Lewis & Clark College.Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies. Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options. Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data to predict and validate oncogenic mutations that promote cancer across tumor types as MasterKey mutations. Black Diamond discovers and develops selective MasterKey therapies against these families of oncogenic mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.
Member Since 2013
Jean-Michel Boers
President and Chief Executive OfficerMr. Boers joined Boehringer Ingelheim in 1998 in Belgium, and advanced through various roles in corporate and operating units, including Corporate Vice President, Marketing and Sales Effectiveness, Country Managing Director for France and Human Pharma head of a European region consisting of mid-sized countries. Mr. Boers came to the U.S. in 2016 as Senior Vice President of the Specialty Care Franchise, and since January 2017, has led the U.S. Human Pharma business. He earned a master’s degree in social and economic history from the University of Nijmegen (Netherlands) and an MBA from the University of Texas.CEO Cancer Gold Standard™
Gold Standard Employer
"We are truly honored to receive this Gold Standard certification to acknowledge our company-wide efforts to make wellness an integral part of our culture and fight cancer in the workplace. In addition to our efforts at home, we are committed to bringing more health to the oncology community, from our research and development of innovative cancer treatments to resources and initiatives that provide education and support to patients, caregivers and healthcare professionals."
Jean-Michel BoersBoehringer Ingelheim Pharmaceuticals, Inc.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report http://annualreport.boehringer-ingelheim.com.Boehringer Ingelheim in Oncology
Cancer takes. Takes away time. Takes away loved ones. At Boehringer Ingelheim Oncology, we are giving patients new hope, by taking cancer on. We are dedicated to collaborating with the oncology community on a shared journey to deliver leading science. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immuno-oncology therapies and intelligent combination approaches to help combat many cancers.
Member Since 2022
Christoph Schweizer is CEO of Boston Consulting Group (BCG), elected May 2021. Prior to this role, he was BCG’s chairman for Central and Eastern Europe and the Middle East. He has also served as a member of the firm’s Executive and Operating Committees since 2014.
Christoph is a member of several leading organizations, including the Business Roundtable and the World Economic Forum’s International Business Council. For the past three years, INvolve People recognized Christoph as a HERoes Advocate Executive Role Model for his work with Women@BCG related to the hiring, promotion, and retention of women.
Throughout his career, Christoph has supported clients in health care and private equity, and across industries in major transformational programs such as digital transformations and post-merger integrations. He is a passionate supporter of a wide range of social impact activities, in particular related to sustainability and fighting climate change.
Christoph joined BCG in 1997, first in Munich, and then New York from 2007 to 2012, before returning to Munich. He received an MBA from University of Texas at Austin’s McCombs School of Business and holds a BA from WHU – Otto Beisheim School of Management in Koblenz.Boston Consulting Group
Boston Consulting Group partners with leaders in business and society to tackle their most important challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was founded in 1963. Today, we work closely with clients to embrace a transformational approach aimed at benefiting all stakeholders—empowering organizations to grow, build sustainable competitive advantage, and drive positive societal impact.
Our diverse, global teams bring deep industry and functional expertise and a range of perspectives that question the status quo and spark change. BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model across the firm and throughout all levels of the client organization, fueled by the goal of helping our clients thrive and enabling them to make the world a better place.
Member Since 2022
Michael F. Mahoney
Chairman and Chief Executive OfficerMichael “Mike” Mahoney is Chief Executive Officer of Boston Scientific Corporation and Chairman of the company’s Board of Directors. Boston Scientific is a global medical technology leader with approximately $12.7 billion in annual revenue and commercial representation in more than 130 countries. Under Mike’s leadership, Boston Scientific is delivering on its mission to transform lives through innovative medical solutions that improve the health of patients around the world. The company’s team of more than 45,000 global employees reaches over 33 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, structural heart, electrophysiology, endoscopy, neuromodulation and urology, and women’s health.
Since joining Boston Scientific, Mike has focused the company on addressing the needs of the evolving healthcare landscape by driving improvements to patient outcomes and increasing healthcare economic efficiency and access. Under his leadership, Boston Scientific has brought many transformational medical devices to market while creating significant value to its shareholders.
Mike’s career spans more than 25 years of success building market-leading medical device, capital equipment and healthcare IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics (MD&D) division of Johnson & Johnson.
Prior to joining Johnson & Johnson, Mike was President and Chief Executive Officer of Global Healthcare Exchange (GHX). For the first 12 years of his career, Mike advanced through a series of leadership roles at General Electric Medical Systems, including General Manager of the company’s Healthcare Information Technology business.Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com.
Member Since2023
Dr. Michalis Papadakis is the CEO and co-founder of Brainomix. He leads the management team, commercial strategy, fund raising, and corporate partnerships. He has grown the company from the ground up, building the company’s global presence and has raised more than £30 million of private investment and public funding. When he founded Brainomix he was the Scientific Director of the preclinical stroke lab at the University of Oxford. He has a BSc Honours in Biochemistry from Imperial College London and a PhD in neurosciences from UCL School of Pharmacy. He has been an invited speaker at international scientific and innovation conferences.Brainomix
Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke, lung fibrosis, and cancer. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company that has innovated award-winning imaging biomarkers and software solutions that are used in more than 30 countries worldwide. Its first product, the Brainomix 360 platform, provides clinicians with the most comprehensive stroke imaging solution, driving faster treatment times and improving functional independence for patients. Follow them on Twitter, LinkedIn and Facebook.
Member Since 2023
James L. Dettore
Founder, Chairman and Chief Executive OfficerJames Dettore, senior strategist and founder of Brand Institute in 1993, has been instrumental in advancing BI’s hallmark of innovation and excellence. In 2004, he extended this legacy by establishing Drug Safety Institute (DSI), which has since become a premier company known for providing unparalleled expertise and cutting-edge regulatory services, setting the industry standard.
Mr. Dettore is an alumnus of the Harvard University Graduate School of Business Administration and currently serves on the Executive Committee of the Harvard University New York Chapter Owner & President Management Program (OPM).
In recognition of BI and DSI’s unwavering support of the pharmacy profession and commitment to patient safety, Mr. Dettore was inducted into the Phi Lambda Sigma Pharmacy Leadership Society in 2020. With over three decades of experience in brand management, he has held key positions at renowned organizations, including PepsiCo, J. Walter Thompson, Hilton International Hotels, and Ralph Lauren.Brand Institute
With gratitude for our remarkable and loyal clientele, Brand Institute has achieved the distinction of being the global leader in pharmaceutical and healthcare-related name and brand identity development. We are honored to have partnered on a portfolio of over 4,600 marketed healthcare brand names and 1,600 USAN/INN (nonproprietary names). This includes over 75 percent of pharmaceutical brand and nonproprietary name approvals globally every year. In the field of oncology alone, we have developed over 850 brand and nonproprietary names, catering to a wide spectrum of clients, from start-up biotech firms to esteemed global pharmaceutical conglomerates. Our success is a direct result of the trust and collaboration of over 1,400 valued clients.
In addition to creating names for pharmaceutical products, Brand Institute has vast experience in developing company names (for new companies as well as rebranding existing ones), clinical trial names, medical device names, OTC product names, technology names, and program names. Our portfolio of services includes name development, trademark searches, market research, visual identity, and regulatory solutions.
Brand Institute’s regulatory services are provided through its wholly owned subsidiary, Drug Safety Institute, which is composed of former regulatory naming officials from global government health agencies, including the U.S. Food and Drug Administration, European Medicines Agency, Health Canada, American Medical Association, and the World Health Organization. These experts offer industry-leading guidance and services related to drug name safety (i.e., preventing medication errors), packaging, and labeling.
Member Since 2004
Giovanni Caforio, MD
Chairman of the Board and Chief Executive OfficerMr. Dr. Giovanni Caforio, M.D., serves as the Chief Executive Officer of Bristol Myers Squibb Australia Pty Ltd. Dr. Caforio serves as Chief Operating Officer at Medarex, Inc. He has responsibility for leading a fully integrated worldwide commercial organization and Medarex-wide functions of Enterprise Services and Global Manufacturing & Supply. He has been the Chief Executive Officer of Bristol Myers Squibb Company since May 5, 2015. He served as Chief Operating Officer Myers Squibb Company since June 9, 2014 and also served as its Chief Commercial Officer and Executive Vice President since November 13, 2013. Dr. Caforio leads the Bristol-Myers Squibb Company’s pharmaceutical business in the U.S. He served as Chief Commercial Officer at Medarex, Inc. Dr. Caforio served as the President of U.S. Pharmaceuticals at Bristol Myers Squibb Company since October 2011. He served as Senior Vice President of U.S. Oncology, Worldwide Pharmaceuticals at Bristol Myers Squibb Company from 2007 to 2009. He served as Senior Vice President of Global Commercialization, Oncology and Immunology at Bristol Myers Squibb from January 2011 to October 2011 and its Senior Vice President of Oncology, Global Commercialization from 2009 to 2010, where he helped re-establish Bristol Myers Squibb as a leader in Oncology, including the launch of YERVOY™, the Bristol Myers Squibb’s innovative immuno-oncology medicine for metastatic melanoma. As a leader, his focus is on developing talented leaders with the diverse experiences and competencies needed for the continued success of the Bristol-Myers Squibb Company. He joined Bristol-Myers Squibb in 2000 as Vice President and General Manager of Italy, in the Worldwide Medicines Group. In 2001, he assumed added responsibility for Greece and Israel, and then all of South East Europe in 2003. Since 2004, he served as Senior Vice President of European Marketing and Brand Commercialization of Bristol Myers Squibb. Since 2007, he served as Senior Vice President of U.S. Oncology of Bristol Myers Squibb. Prior to joining Bristol Myers Squibb, he spent 12 years with Abbott Laboratories in a number of leadership positions. He has been a Director of Bristol Myers Squibb Company since June 9, 2014. He served as a Director of Capital Health System, Inc. until June 17, 2016. Dr. Caforio holds an M.D. from the University of Rome.CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Employer Since 2016 | Gold Standard China Employer Since 2018 | Gold Standard Global Employer Since 2019Receiving the CEO Cancer Gold Standard Accreditation underscores Bristol-Myers Squibb’s commitment to transforming cancer care as well as our unwavering commitment to our patients and our people.
Giovanni Caforio, MDGold Standard Task force Participation
Task Force Member(s): David Shepperly, MD, MHS, FACOEM, Head of Employee Health and FitnessLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Christopher Boerner PhD, President and Head US; Fouad Namouni MD, Oncology Development HeadBristol Myers Squibb (BMS)
Bristol Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS and, rheumatoid arthritis.
At Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.
The strategy is working. In recent years our total return for shareholders, including dividends, has been among the best in the industry. We outperformed most mega pharma companies, diversified companies and pure biotech companies. Reflecting our long-standing commitment to deliver shareholder value, our company has paid dividends to stockholders for more than 300 consecutive quarters.
We have delivered 12 new medicines to patients in the past 7 years.
Our R&D organization is considered among the most productive in the industry. And the business development strategy of innovative alliances, partnerships and acquisitions further enhances our internal capabilities. Our full array of transactions encompasses many of our key disease areas, along with new areas of focus such as genetically defined diseases and fibrotic diseases.
Pursuing our Mission also means we are working to provide patient access to health care. We are striving to reach that goal through public/private partnerships like SECURE THE FUTURE, our groundbreaking $150 million program to help confront HIV/AIDS in Africa while also developing new, innovative programs to help patients with cancer, hepatitis B and hepatitis C. In addition, through our patient assistance programs, we provide free medications to qualifying patients with financial hardship in the U.S.
Innovation is critical for successfully executing our BioPharma strategy. That innovation is enhanced by a diverse workforce and an inclusive culture. Bristol-Myers Squibb has been recognized year after year as one of the best companies for female executives and working mothers. We’ve also been recognized by the Human Rights Campaign Foundation’s Corporate Equality Index for achieving a perfect score for four consecutive years.
Preservation of our natural resources also represents one of our key commitments. At many of our facilities worldwide, our company is integrating comprehensive energy management, pollution controls and other practices to reduce environmental impacts. Bristol-Myers Squibb is recognized among the leading sustainability-driven companies.
Ultimately, our success as a BioPharma leader is measured by the difference we make in the lives of patients.
Member Since 2020
Ken Keller
President and CEOKen Keller is President and CEO of Daiichi Sankyo, Inc. He also leads the U.S. Business and serves as a member of Daiichi Sankyo’s Global Management Committee. Mr. Keller joined Daiichi Sankyo Inc. in 2014.
Through his work with Daiichi Sankyo, and prior to that with Amgen Inc., Mr. Keller has more than 30 years of experience in the pharmaceutical industry. He has led multi-billion dollar businesses in the U.S. and Europe.
Through leadership roles in multiple markets, across cultures and within different healthcare systems, Mr. Keller has successfully launched numerous biologic products in therapeutic areas ranging from oncology to bone health to nephrology to inflammatory diseases, transformed businesses, and delivered sustainable revenue and profit growth
Since joining Daiichi Sankyo, Inc., Mr. Keller has shifted the structure of the U.S. business to focus on launching multiple oncology therapeutics in the coming years. He is known for his inclusive leadership approach and his passion for bringing innovative drugs to patients in need.
Mr. Keller is a member of the PhRMA Board of Directors and was previously a board member of the Association of the British Pharmaceutical Industry. He holds a Bachelor of Science degree in Business from Saint John’s University and a Master of Business Administration degree from Loyola Marymount University.Daiichi-Sankyo
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. It provides innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, the company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Member Since 2006
Jacob Van Naarden
Executive Vice President, Eli Lilly and Company; President, Loxo at LillyJake Van Naarden serves as executive vice president of Eli Lilly and Company and president of Loxo at Lilly. In this role, Jake oversees all aspects of oncology spanning discovery through commercial. Jake joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. Following the acquisition, Jake played a key role in establishing the Loxo at Lilly research and development program. In his earlier roles, Jake worked in various biotechnology investing, operational, and advisory capacities, including positions with HealthCorManagement, Aisling Capital, and Goldman Sachs. Jake received his A.B. degree in molecular biology from Princeton University.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2011"At Lilly, our commitment to making life better goes beyond the medicines we make – it’s at the very heart of our business. We are honored to have been designated a CEO Cancer Gold Standard accredited corporation, which underscores the importance we place on the well-being of our employees. We in Lilly Oncology, continually strive to create an environment of wellness for our employees, one that provides them with the preventive care and education they need to live happy, healthy and productive lives."
Jacob Van NaardenGold Standard Task force Participation
Task Force Member(s): Leslie M Ayres, RN, Manager Corporate Health Services; Charles Williams, Senior Director – Corporate Health ServicesLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Susan Mahony, PhD, Senior Vice President and President, Lilly Oncology; Anwar M. Hossain, Research ScientistProject Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumData Provider
Since 2015Eli Lilly and Company
Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
We were founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that meet real needs. More than a century later, we are passionate about building on this precedent in our continued pursuit to make life better for individuals, communities, and the world around us.
Our heritage and our values are the foundation of our promise to unite caring with discovery to make life better for people around the world.
Our mission
We make medicines that help people live longer, healthier, more active lives.
Our values
Integrity, excellence, respect for people
Our vision
We will make a significant contribution to humanity by improving global health in the 21st century.
MEMBER SINCE 2022
John Potthoff, Ph.D.
CEOA respected veteran with nearly 28 years in the clinical research services industry, John Potthoff, Ph.D., has directed major business for a number of companies.
Potthoff’s career began with a series of executive roles involving increasing responsibility at PPD. After seven years, he left to become the founder and CEO of Tanistry, Inc., a contract research organization focused on the central nervous system. After selling Tanistry to INC Research in 2001, he joined INC Research, an 11-year career step that culminated in the role of COO.
Following his success at INC Research, Potthoff assumed the position of CEO at Theorem Clinical Research in 2011. In four years, he doubled its revenue, sales, backlog, and earnings before selling to Chiltern International in 2015.
Potthoff is NACD Directorship Certified and currently serves on the board of directors of Chembio (NASDAQ: CEMI) and previously served on the board of directors for Chiltern, Advarra, and Synteract.Elligo Health Research
Elligo Health Research® accelerates clinical trials through healthcare with access to over 150 million known patients and their HIPAA-compliant healthcare data, our IntElligo® Research Stack technology, and our PatientSelect identification and engagement model. Coupled with the largest Known Patient Access Network, Elligo’s Site Solutions enable healthcare practices and research sites to participate in clinical trials. By adaptive engagement of known patients and physicians, we accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.
MEMBER SINCE 2012Andrew Paterson
President of EMD Serono and Global Head of Innovative Medicine Franchises for Merck KGaA, Darmstadt, GermanyAs President of EMD Serono and Global Head of the Innovative Medicine Franchises for Merck KGaA, Darmstadt, Germany, Andrew Paterson leads the North American biopharmaceutical business across the U.S. and Canada in addition to leading the global oncology and neurology & immunology specialty medicine franchises for the healthcare business of Merck KGaA, Darmstadt, Germany.
Prior to this, Paterson served as Senior Vice President, Head of U.S. and Global MS Franchise, where he oversaw all commercial operations for the franchise in the US and also led global marketing efforts for our MS therapies.
In his 23 years with the company, Andrew has held positions in Local, Regional and Global commercial functions across a variety of therapeutic areas including Neurology, Endocrinology, Fertility and Cardio-vascular.
He began his career with Merck KGaA, Darmstadt, Germany in 1998 as a Medical Sales Representative in the UK. He subsequently took on roles of increasing responsibility including first line Sales Manager, Marketing Manager and Business Unit Director. Global and Regional leadership roles followed. Most recently, his focus was on the preparation and execution of the global launch of a new therapy in MS and progressing pipeline therapies toward commercialization.
Paterson holds a BSc (Hons) in Biological Science from the University of Edinburgh and an Executive MBA from Ashridge Management College.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2011Gold Standard Task force Participation
Task Force Member(s): Ellen Spencer, Manager, Office of the PresidentLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Zhen Su, MD, MBA, Vice President of Medical OncologyProject Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumData Provider
Data Provider to Project Data Sphere, LLC since 2015EMD Serono
We are the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. We focus exclusively on specialty care – integrating cutting-edge science with industry-leading patient support.
At EMD Serono, we recognized the potential of specialty pharmaceuticals and patient care long ago, and have been dedicated to delivering on their promise ever since.
We have a legacy of both trying to find solutions to hard to treat conditions, as well as developing patient assistance programs that help ensure that those who need our therapies are able to access them.
As one of the top five U.S. companies exclusively focused on specialty care, we see our innovation as a matter of balancing science with emotion – integrating our top minds in research and development with the insights from patients and health care practitioners confronting real- world concerns.
MEMBER SINCE 2015
François Maisonrouge
Senior Managing DirectorFrancois Maisonrouge is a Senior Managing Director in Evercore Partners’ advisory business with 31 years of relevant experience.
At Evercore, among other transactions, Mr. Maisonrouge was involved in advising Medivation on its sale to Pfizer, AstraZeneca on the sale of its anti-infectives business to Pfizer, Shire on its acquisitions of Baxalta and Dyax, Shire on its defense across from Abbvie, AstraZeneca in its defense across from Pfizer, Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories, Bristol-Myers Squibb on its acquisition of Amylin and sale of half of its interest in Amylin to AstraZeneca, Fenwal on its sale to Fresenius, Terumo on its acquisition of CaridianBCT, Sanofi on its acquisition of Genzyme and of Merck’s 50% stake in Merial, TPG on its acquisition of IMS Health, and Wyeth on its combination with Pfizer.
Prior to joining Evercore, Mr. Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology.
Mr. Maisonrouge has an M.S. in Engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School. He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and a Director of the Pasteur Foundation. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d’Honneur.Life Sciences Consortium
LSC Task Force Participation
Task Force Member(s): François Maisonrouge, Senior Managing DirectorEvercore Partners LLC
Evercore is a premier independent investment banking advisory firm.
We founded Evercore in 1995, on the premise that clients would be best served by an investment banking firm free of the conflicts of interest inherent to large, multi-product financial institutions. We believed our model would attract the most talented senior finance professionals to our firm. We believed that by maintaining the highest standards of excellence we could create a firm unlike any other in terms of capabilities to advise on highly complex strategic transactions, dedication to our client and our experience and professionalism.
Today, we serve a prominent and diverse set of clients and investors, including leading multinational corporations, large institutional investors and financial sponsors, and high net worth individuals.
Our global expansion continues in order to ensure the worldview and international knowledge base that is now critical to all investors. Today, our offices in North America, Europe, Mexico, Brazil, Hong Kong and Singapore are complemented by strategic alliances with leading firms in China, Japan, India, Korea, Australia and Argentina.
We always strive to enhance our capabilities and expand our global reach thereby providing the highest caliber of various services to our clients.
MEMBER SINCE 2020
Brian Alexander, MD, MPH
Chief Executive OfficerDr. Brian Alexander was named Chief Executive Officer of Foundation Medicine in March 2021. He previously served as the company’s Chief Medical Officer since 2019, and is a practicing radiation oncologist specializing in neuro-oncology at Dana-Farber/Brigham and Women’s Cancer Center, and a Senior Lecturer at Harvard Medical School.
Since joining the company in September 2018 as a Senior Vice President of Clinical Development, Dr. Alexander has played a pivotal leadership role in Foundation Medicine’s decision insights strategy, helping oncologists, both in community and academic settings, determine the right treatment, at the right time, for each unique patient. Under his leadership, Foundation Medicine’s medical team has expanded its molecular tumor board program to include over 90 leading oncology centers globally, launched a cross-functional genomics and health disparities effort, and has developed hundreds of studies and publications to advance the clinical utility of genomic profiling.
Dr. Alexander was the founding director of the Program in Regulatory Science at the Dana-Farber Cancer Institute and the Harvard/MIT Center for Regulatory Science. He also co-founded the Global Coalition for Adaptive Research, a non-profit organization focused on clinical trial innovations to accelerate the discovery and development of cures for patients with rare and deadly diseases, and served as chair of the FDA/Project Datasphere task force on external control arms. Dr. Alexander is an affiliated researcher at the MIT Laboratory for Financial Engineering and affiliated faculty of the Harvard Kennedy School Healthcare Policy Program. He was named to Boston Magazine’s “Top Doctors List” in 2019, 2020, and 2021.
Previously, Dr. Alexander served as a White House fellow and Special Assistant to the Secretary of Veterans Affairs, where he helped prepare the VA for the transition of administrations, worked to develop a public reporting system for quality, and served as a health policy advisor to the Secretary. Dr. Alexander organized the standup of the VA’s Coordinating Council on National Health Reform and directed the activities of its multi-team Health Reform Working Group. He was also a member of the Institute of Medicine’s Committee on the Governance and Financing of Graduate Medical Education.
Dr. Alexander’s research interests focus on innovations in clinical evidence generation to support the development of therapeutics, biomarkers, and novel endpoints. He co-authored a book titled “Diagnostic Test Interpretation and Reasoning Under Uncertainty,” detailing the use of Bayesian approaches to clinical decision-making. Dr. Alexander was the founding principal investigator of INSIGhT, a multi-institutional genomic biomarker-based Bayesian adaptively randomized trial for patients with glioblastoma. He is the recipient of the Burroughs-Wellcome Innovations in Regulatory Science Award for his work applying such approaches to clinical trial design.
Dr. Alexander received his B.A. from Kalamazoo College, M.D. from the University of Michigan Medical School, and M.P.H. from the Harvard School of Public Health. He completed his training in radiation oncology at the Harvard Radiation Oncology Program.CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Employer Since 2016Foundation Medicine, Inc.
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.
Alexander Hardy
Chief Executive Officer, GenentechAlexander Hardy is chief executive officer of Genentech, a member of the Roche Group. He previously served as head of Global Product Strategy, Roche Pharmaceuticals and has served in a number of key leadership positions across Genentech and Roche.
As head of Global Product Strategy, Alexander led cross-functional teams to develop and launch new medicines and indications in more than 100 countries worldwide. He also cochaired Roche’s late-stage portfolio committee, with direct accountability for new formulations and devices, geographic expansion, and post-marketing investments.
From 2014 to 2016, Alexander was head of Asia Pacific for Roche Pharmaceuticals, overseeing 19 countries and more than 6,000 employees. Prior to this, starting in 2005 Alexander held several senior management positions at Genentech including heading patient access services and leading commercial operations for a range of medicines and therapeutic areas from HER2-positive cancer to influenza and neuroscience.
Prior to Genentech, Alexander held leadership positions at Novartis as head of market access for Europe, country head for Denmark, and business unit head and director of strategic planning and new product development in the U.K. Alexander completed his undergraduate education at Cambridge University in the U.K. and earned his MBA at the University of Michigan. He currently lives in Basel, Switzerland, and is married with three daughters.
FOUNDING MEMBER
Emma Walmsley
Chief Executive OfficerEmma Walmsley is CEO Designate of GSK. She will formally succeed Andrew Witty as GSK CEO when he retires on 31 March 2017. She has been a member of GSK’s Corporate Executive Team since 2011. She joined the GSK Board on 1 January 2017.
Previously, Emma was the CEO of GSK Consumer Healthcare, a Joint Venture between GSK and Novartis which was created in March 2015. With a turnover of £6bn in 2015, GSK Consumer Healthcare is one of the world’s largest consumer health companies, developing and marketing products in Wellness, Oral Health, Nutrition and Skin Health.
Prior to this Emma was President of GlaxoSmithKline Consumer Healthcare. She joined GSK in 2010, with responsibility for Consumer Healthcare, Europe.
Prior to joining GSK, Emma worked with L’Oreal for 17 years where she held a variety of marketing and general management roles in Paris, London and New York. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China.
Emma was a non-executive director of Diageo plc from 1 January – 21 September 2016.
Emma holds an MA in Classics and Modern Languages from Oxford University.CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Employer Since 2006 | Global Gold Standard Employer Since 2017Gold Standard Task force Participation
Task Force Member(s): David Siebens, MD, PhD, Medical Services Director – US; Samuel Pelk, Global Health AdvisorLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Axel Hoos, MD, PhD, Vice President, Oncology R&D, DPU Head, Immuno-Oncology Combination; Jamey Millar, Senior Vice President, Managed Markets & Government AffairsGlaxoSmithKline
We are a science-led global healthcare company. We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare. We have a significant global presence with commercial operations in more than 150 countries, a network of 89 manufacturing sites, and large R&D centres in the UK, USA, Belgium and China
FOUNDING MEMBER
John Crumpler
General Partner, Hatteras Venture PartnersJohn co-founded Hatteras in 2000 after a successful career as a technology entrepreneur. After a decade in politics and public policy, he was founder and CEO of E-Comm, Inc., a software development and services firm specializing in remote and mobile computing. Following E-Comm’s acquisition by XcelleNet, Inc. (XNET), John ran the services division there until the company was acquired by Sterling Commerce (SE). Following the acquisition John founded Hatteras with Clay Thorp.
At Hatteras, John is responsible for the firm’s investments in healthcare and life science information technology, and overall fund operations.
With his partners at Hatteras John has helped build a seed and early stage venture capital partnership with over $600 million under management in six funds. In that time, he has served on the boards of Synthematix, a chemistry informatics company that was acquired by Symyx Technologies (SMMX); Clinverse, a financial lifecycle management technology provider to contract research organizations (CROs) and pharmaceutical companies, acquired by Bioclinica, Inc.; Bivarus, a survey-based health analytics company acquired by Press Ganey; NurseGrid, the nation’s most widely distributed nurse scheduling platform, acquired by HealthStream; and Medfusion, a leading patient engagement platform, acquired by NextGen. John currently serves on the boards of Iris Healthcare, Elligo Health Research, Wildflower Health, Jumo Health, and as an observer at SafeRide and Clinipace Worldwide. He holds an A.B. from Harvard University.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2016"The CEO Cancer Gold Standard is the best way I know for any organization to make a real difference in the fight against cancer."
John CrumplerHatteras Venture Partners
Hatteras Venture Partners is a venture capital firm formed to invest primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. The firm will typically invest in companies located in the research-driven regions of North Carolina and the Southeastern United States, which are undercapitalized in comparison to New England and California. Core to the mission of Hatteras Venture Partners is a belief that entrepreneurial innovation will create valuable new products that will transform the practice of medicine and create value for our investors. As entrepreneurs, operators, and investors, we are dedicated to the success of our companies and to the men and women who create them. Founded in 2000 and based in Durham, NC, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With five funds, the firm has approximately $350 million under management. Hatteras is an Innovation to Impact sponsor of the Council for Entrepreneurial Development, a member of NCBIO, and an active volunteer in support of North Carolina and Southeast regional biotech activities.
MEMBER SINCE 2014
Riccardo Braglia, MBA
Helsinn Group Vice Chairman & Group Chief Executive OfficerRiccardo Braglia, Helsinn Group’s Vice Chairman and CEO, Managing Director and Member of Helsinn Holding’s Board of Directors, Switzerland and Executive Committee for Helsinn Group’s strategic management, has a wealth of over 30 years of international experience in the pharmaceutical industry. Mr. Braglia heads the family-run, privately owned pharmaceutical company, the Helsinn Group, founded in 1976, with a worldwide presence and focus on cancer therapeutics and supportive care.
Mr. Braglia is a Board Member of Helsinn Healthcare, Switzerland, Helsinn Advanced Synthesis, Switzerland, Helsinn Birex Pharmaceuticals, Ireland and Chairman of Helsinn Therapeutics, USA. He is also Président Directeur Général – Gérant Associé of Helsinn International Services, Monaco, Principality of Monaco and Chairman of the Helsinn Investment Fund, Luxembourg. Mr. Braglia serves as a Board Member of two portfolio companies of the Helsinn Investment Fund, QuantumDx Group Limited, UK and GreenBone Ortho S.R.L., Italy. He is also Co-founder and Board Member of Lyfebulb, USA, and a Board Member of Thorne Research, Greenwich CT/USA, Wellness-Fx and Health Elements.com, all US companies. Mr. Braglia is a member of the Board of the Conquer Cancer Foundation, USA. Mr. Braglia is also active in the investment community as an advisor to the New York City-based venture capital firm Windham Ventures.
Riccardo Braglia holds a degree in Business Economics with a specialization in Business Industrial Management from the Luigi Bocconi University of Milan, Italy.CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Employer Since 2015 | Global Gold Standard Employer Since 2015"Helsinn’s mission is to bring respect, integrity, and quality to our products, services and all that we do to improve health and quality of life in every person affected by cancer. We are honored to be accredited CEO Cancer Gold Standard which means quality of life for our employees and is an additional step forward to reach our mission."
Riccardo Braglia, MBALife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Sergio Cantoreggi, PhD, Chief Scientific Officer & Global Head of R&DHelsinn Healthcare SA
The Helsinn Group is one of the world’s leading supportive cancer care companies. Our business model is built on forging lasting alliances with worldwide partners who share our vision. Through a mix of integrated early and late stage licensing programs and our own development, we have developed a comprehensive portfolio of effective pharmaceuticals and specialist therapies that are sold in over 90 countries, and a late stage pipeline of future cancer therapies which will meet unmet medical needs in the treatment of cancer.
MEMBER SINCE 2006
W. Richard Staub III
President, Research & Development SolutionsRichard Staub is president of the Research & Development Solutions global business unit at IQVIA, leading the world’s largest contract research organization (CRO). Supported by high-powered information and technology assets, the clinical experts in Research & Development Solutions leverage comprehensive, evidence-driven trial design, accelerate site activation and patient recruitment, and optimize trial execution. Richard also serves as chair of the Research & Development Solutions Executive Committee.
Previously, he led Novella Clinical, a specialty clinical research organization acquired by Quintiles in 2013. Richard joined Novella in 2004 and served as both president and CEO. Under his leadership, Novella became a distinctively agile, results-oriented CRO in the highly complex and fast-growing areas of specialty pharma and medical technology. Prior to Novella, he was senior vice president of global business development for one of the world’s largest CROs. Richard’s career in the pharmaceutical industry began at Zeneca Pharmaceuticals in 1989 where he was given increasing responsibilities as a medical and hospital sales representative, cardiovascular portfolio analyst and marketing manager.
Richard has a bachelor’s degree in Economics from the University of North Carolina at Chapel Hill.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2007Gold Standard Task force Participation
Gold Standard Subcommittee Chair, Accreditation Review Board Member & Member: Ann Skye, BSN, MPH, Associate Director, Employee Health ManagementGlobal Gold Standard Task force Participation
Global Gold Standard Subcommittee Chair and Member: Ann Skye, BSN, MPH, Associate Director, Employee Health ManagementLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Jeffrey A. Spaeder, MD, Chief Medical & Scientific Officer; Alan Metz, MD, Senior Vice President and Managing Director, Strategic PartnershipsIQVIA
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIA’s approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.IQVIA.com.
MEMBER SINCE 2022
Adam Pelligrini
CEO and Co-FounderAdam Pellegrini is the Co-Founder and CEO of Jasper Health. In this role, Adam will grow Jasper into the leading platform enabling cancer patient navigation, management, and care. Previous to Jasper, Adam was the Senior Vice President of Virtual Care and Consumer Health Innovations for CVS, Aetna and Caremark, leading new product ideation and execution across the portfolio. Before CVS, Adam was the SVP and General Manager of Fitbit Health Solutions which was tasked with helping Fitbit connect its products, information, data and insights with employers, health plans and hospital systems in new and innovative ways.
Pellegrini brings more than 21 years of experience across multiple sectors of the healthcare industry including consumers, providers, insurers, health technology and nonprofits. Before Fitbit, Adam created the Digital Health strategy for Walgreens Boots Alliance as the Vice President of Digital Health, responsible for revolutionizing how the global chain approached omni-channel digital healthcare, including advancing the company’s integration with wearables, launching telemedicine and advancing their core digital pharmacy platforms. As part of his work with Walgreens, his team led the largest retail mHealth integration of more than 1 million connected devices and launched the company’s first integration of wearables, including Fitbit devices, with its Balance Rewards program which rewards customers for making healthy choices.
Prior to WBA, Pellegrini led teams building the future of Digital Health including Microsoft HealthVault and HealthyCircles and was the first online strategy leader for the American Cancer Society. Adam started his career in the U.S. Army as an Operating Room Technician also working in aviation medicine, as an emergency room technician and leading occupational medicine initiatives for major health systems.Jasper Health
Jasper Health is a digital guiding, navigation, and engagement experience that improves the lives of people living with cancer, those at high risk for cancer, and their caregivers. Its all-in-one oncology platform provides psychosocial support interventions while enabling connected care with the broader healthcare system. Our team includes seasoned leaders with decades of experience in digital health, clinical care, data science, and consumer engagement. Founded at Redesign Health, a company that powers innovation in healthcare, we believe that powerful technology and passionate people can relieve some of the stress of organizing care. To learn more, visit www.hellojasper.com.
FOUNDING MEMBER
Joaquin Duato
Vice Chairman of the Executive Committee of Johnson & JohnsonJoaquin Duato is a globally experienced, values-driven health care business leader and currently Vice Chairman of the Executive Committee of Johnson & Johnson, the world’s premier health care company. Joaquin is responsible for the Company’s Pharmaceuticals and Consumer sectors, along with Supply Chain, Technology and the Health & Wellness groups. He is a respected industry leader and past Chairman of the Pharmaceutical Research and Manufacturers of America.
As a member of the company for more than 30 years, Joaquin played an instrumental role in leading the turnaround of Johnson & Johnson’s Pharmaceuticals sector. Joaquin was named Company Group Chairman of the Americas in 2009. He then continued leading the global transformation upon his appointment to his role as Executive Vice President and Worldwide Chairman, Pharmaceuticals in 2011. During that time, the sector grew into what is today the third-largest innovative pharmaceutical company globally.
More recently in his role as Vice Chairman, Joaquin provides strategic direction for the sectors and functions he oversees. He helped guide the transformation of Johnson & Johnson’s Consumer Health sector, under which the business has renewed its focus on Self-Care and Skin Health brands that are rooted in science and endorsed by professionals. Additionally, Joaquin is championing the use of new technologies across Johnson & Johnson so the company can continue leading in a digital world, with a focus on the application of Data Science, Intelligent Automation and other digital technologies.
As a dual citizen of Spain and the United States with extensive experience living and working on-the-ground on multiple continents, Joaquin brings a unique international perspective to his work. His global experience has given him an appreciation for the value of diversity of thought and opinions, which he brings to bear externally as a UNICEF USA Board Member, Tsinghua University School of Pharmaceutical Sciences Advisory Board Member and Hess Corporation Board Member, and internally as the Executive Sponsor of the African Ancestry Leadership Council. His commitment to nurturing a culture of diversity and inclusion was recognized by the Healthcare Businesswomen’s Association (HBA) when he was named 2017 Honorable Mentor. Joaquin has an undergraduate degree in economics and business, a Master of Business Administration degree from ESADE Business School in Barcelona and a Master of International Management degree from Thunderbird in Phoenix, Arizona. Follow Joaquin on Twitter at @joaquinduato.CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Employer Since 2006 | Global Gold Standard Employer Since 2013It’s an honor to earn the Gold Standard accreditation for the 10th consecutive year, and it’s a recognition that I attribute to our strong culture of health. Our employee wellness programs at Johnson & Johnson have, undoubtedly, led to a healthier and more productive, engaged and satisfied workforce, which reaffirms our belief that an investment in our employees’ health is an investment in our company’s health. – Alex Gorsky
Joaquin DuatoGold Standard Task force Participation
Task Force Member(s): Marcelo Targino, MD, MPH, FACOEM, FACP, Chief Health Officer & Corporate Medical Director; Jennifer Bruno, Vice President, Global Health ServicesGlobal Gold Standard Task force Participation
Member Global Gold Standard Subcommittee: Marcelo C. Targino, MD, MPH, FACOEM, FACP, Chief Health Officer & Corporate Medical DirectorLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Wayne Rackoff, VP Clinical Oncology; William Hait, MD, PhD, Global Therapeutic Area HeadProject Data Sphere, LLC
an independent initiative of the Life Sciences ConsortiumData Provider
Pioneering Data ProviderJohnson & Johnson
Caring for the world, one person at a time… inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Our Family of Companies comprises:
•The world’s sixth-largest consumer health company
•The world’s most comprehensive medical devices business
•The world’s sixth-largest biologics company
•And the world’s fifth-largest pharmaceuticals company
We have more than 265 operating companies in more than 60 countries employing approximately 126,500 people. Our worldwide headquarters is in New Brunswick, New Jersey, USA.
MEMBER SINCE 2006
Peter W.T. Pisters, MD
PresidentOfficially named president in September after being unanimously selected as the sole finalist by the UT System Board of Regents, Peter WT Pisters, MD previously served MD Anderson in faculty and leadership roles for more than 20 years. Most recently, he was president and chief executive officer of the University Health Network (UHN) in Toronto, Canada.
Pisters oversaw more than 14,000 employees and a $400 million research enterprise at UHN, Canada’s largest hospital-based research program, beginning in January 2015. Prior to his appointment at UHN, he was vice president for MD Anderson’s regional care system, comprising multiple Houston-area locations.
Pisters initially joined MD Anderson’s faculty in 1994 as assistant professor of Surgery, rising to full professor with tenure in 2004. His specialties are sarcoma and gastrointestinal cancer, and he remains a board-certified surgeon. He also holds a master’s degree in health care management from Harvard University.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2007Gold Standard Task force Participation
Task Force Member(s): Bret J. Belfer, Director, Employee Wellness and RecognitionLife Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Donald A. Berry, PhD, Professor, Department of Bio-statisticsThe University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention.
Mission
The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.
Vision
We shall be the premier cancer center in the world, based on the excellence of our people, our research-driven patient care and our science. We are Making Cancer History.
Core Values
Caring: By our words and actions, we create a caring environment for everyone.- We are sensitive to the concerns of our patients and our co-workers.
- We are respectful and courteous to each other at all times.
- We promote and reward teamwork and inclusiveness.
Integrity: We work together to merit the trust of our colleagues and those we serve.- We hold ourselves, and each other, accountable for practicing our values.
- We communicate frequently, honestly and openly.
- By our actions, we create an environment of trust.
Discovery: We embrace creativity and seek new knowledge.- We help each other to identify and solve problems.
- We seek personal growth and enable others to do so.
- We encourage learning, creativity and new ideas.
MEMBER SINCE 2020
Elcin Barker Ergun
Chief Executive OfficerElcin Barker Ergun worked in Global, Regional and Local leadership roles in Pharma Industry for more than 20 years including Commercial, Finance and Innovation leadership.
Elcin is Member of the Board of Directors and CEO of Menarini Group as of September 2019 based in Florence.
Prior to that, she was EVP, President of New Businesses, Merck KGaA Healthcare based in Boston responsible for an entity carrying out external R&D collaborations to create new businesses with estimated peak sales of $5-9billion.
Before that, she was EVP, Head of Global Commercial for Merck Serono based in Germany, where she was responsible for a P&L of €4.5 billion and over 5,000 people and achieved significant business and leadership transformation across global operations.
Prior to that, she was SVP, Head of Intercontinental Region comprising of 69 countries across Middle East, Africa, Turkey, Russia/CIS with a P&L of €650 million. During her term, topline grew by 40%. Prior to that, she was Managing Director of Turkey, where she started up and grew the operation to become a strong specialty player attaining market leadership in each key business.
In her earlier career, Elcin held several finance roles as subsidiary CFO Smithkline Beecham and as subsidiary CFO for Honeywell where she was responsible for full spectrum of finance, accounting, treasury, tax and reporting functions. She also spent one year in UK at Northern European HQ of Honeywell leading marketing and supply chain projects. She started her career as a software engineer and worked for ITT in Amsterdam for 5 years in IT Management.Menarini Group
Menarini Group, the leading Italian pharmaceutical company in the world, has 17,640 employees in 136 countries, including the US in San Diego and Philadelphia.
FOUNDING MEMBERRobert M. Davis
Chief executive officer and president
Rob Davis is chief executive officer and president of Merck.
Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company’s chief financial officer.
Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021 and CEO and a member of the board of directors on July 1, 2021.
Prior to joining Merck, Rob was corporate vice president and president of Baxter’s Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s Renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.
Rob serves on the board of directors for Duke Energy Corporation and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a board member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most.
Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.CEO Cancer Gold Standard™
Gold Standard Employer
Since 2018Merck is at the forefront of cancer research, with inventions that are helping to transform prevention and treatment of the disease. However, our commitment to tackling cancer extends beyond our scientific research. At Merck, our employees are our most critical resource, which is why we’re pleased to be recognized with The Gold Standard. When our employees feel their best, they can be and do their best, which is crucial to helping us achieve our mission of improving and saving lives.
Robert M. DavisGold Standard Task force Participation
Task Force Member(s): Virgina Peddicord, DirectorLife Sciences Consortium
LSC Task Force Participation
Task Force Leadership: Kald Abdallah, MD, PhD, AVP, US Oncology Global Medical Affairs & Leader, Oncology Global Medical Affairs
,
Task Force Member(s): Roy D. Baynes, MD, PhD, Senior Vice President & Head of Global Clinical Development, Chief Medical Officer; Eric Rudin, MD, Vice President and Therapeutic Area HeadMerck & Co., Inc.
We are a global healthcare company with a 125-year history of working to make a difference. To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
1204 Village Market Place, Suite 288
Morrisville, NC 27560 (919) 531-3123 |
© COPYRIGHT 2024 CEO Roundtable on Cancer. ALL RIGHTS RESERVED.
|